Navigation Links
IRIDEX Reports 2013 Third Quarter Results
Date:10/31/2013

MicroPulse enabled laser units this quarter compared to last year's third quarter and standing room only in a recent training seminar at a large trade show in Amsterdam. Our observation that physicians and healthcare policy makers in industrialized and developing nations are adopting value-based medicine practices and policies continues to be validated and ties in to the tremendous value our MicroPulse and continuous wavelength laser systems provide both to our customers and their healthcare systems for the treatment of sight threatening diseases.  This realization creates a growing tailwind for our business and bodes well for our future." 

Moore concluded, "These positive results underscore the cultural shift at the Company allowing us to better execute in the marketplace. We are looking forward to an active fourth quarter in which we will continue to accelerate our market-centric initiatives, introducing three new products at the AAO conference in November and targeting additional multi-unit tenders in countries across Europe, the Middle East and South America."

Revenues for the first nine months of 2013 were $27.7 million, up 12% from $24.6 million in last year's first nine months. Operating income for the first nine months of 2013 was $2.1 million, up $3.3 million from an operating loss of $1.2 million in last year's first nine months. Net income from continuing operations for the first nine months of 2013 was $1.8 million compared to a loss of $0.4 million for the first nine months of 2012, or earnings of $0.18 per share compared to a loss of $0.05 per share on a diluted basis.

During the third quarter 2013, the Company continued to execute its share repurchase program. In total, approximately 37,000 shares have been repurchased at an average price of $5.31 under the plan approved in February 2013.

Conference Call
IRIDEX management will conduct a conference call later today, Thursday, October 31, 2013 at 5:00 p.m. East
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IRIDEX Announces Third Quarter 2013 Conference Call and Release Date
2. IRIDEX to Present at Craig-Hallum 4th Annual Alpha Select Conference
3. IRIDEX to Present at 2013 Wedbush Securities Life Sciences Management Access Conference
4. IRIDEX Reports 2013 Second Quarter Results; $9.2 Million Record Q2 Revenue
5. IRIDEX Announces Second Quarter 2013 Conference Call and Release Date
6. IRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock
7. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
8. IRIDEX Reports 2013 First Quarter Results
9. IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries
10. IRIDEX Announces First Quarter 2013 Conference Call and Release Date
11. IRIDEX Announces Global Distribution and Supply Agreement with Peregrine Surgical, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... is looking to give exercise enthusiasts the extra nudge ... shows that a cyber buddy can help. , The ... Journal , is the first to indicate that although ... exercise, a software-generated partner also can be effective. , ... can still motivate people to give greater effort while ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
Breaking Medicine News(10 mins):Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2
... the overweight , , MONDAY, March 3 (HealthDay News) -- ... to have breathing-related problems during surgery, says a University ... looked at 1,380 normal-weight, 351 overweight, and 294 obese ... surgery, found that obese children had a higher rate ...
... WASHINGTON, March 3 To commemorate Patient,Safety Awareness Week ... Epidemiology (APIC) is issuing five steps every,patient can take ... of,developing an infection during a hospital stay., Visit ... learn,more., 1) First Step, Hospital Prep, Most ...
... and advocate for affordable health coverage. Health, labor, faith ... ... Leaders from throughout Michigan,including representatives of insurers, health systems, labor, ... newly formed,Michigan Cover The Uninsured Network (MCTUN). The goal of the ...
... Smith & Nephew,Inc.,s (NYSE: SNN ; ... approval of its award winning OXINIUM(TM),oxidized zirconium technology., ... company to offer such a,revolutionary and award winning ... alloy with a ceramic bearing surface. OXINIUM,provides low ...
... OrthoSynetics(TM), the largest,provider of business services to orthodontic ... Director, IT Infrastructure., "Hiring Brad is in ... and providing the most innovative technology to,our doctors ... CEO,OrthoSynetics(TM). "In a very short period of time, ...
... Super Bowl champ O.J. Brigance,who recently confirmed a ... at The Robert Packard Center for ALS Research ... by the Center to fund,research to find a ... Gehrig,s,Disease.", (Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 ), ...
Cached Medicine News:Health News:Obese Children Face More Complications During Surgery 2Health News:APIC Issues Recommendations on How to Have a Healthy Hospital Stay 2Health News:Michigan Leaders Join Network to Push for Coverage of State's 1.4 Million Uninsured 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 3Health News:Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure 2Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Medicine Products: